Francis Van Parys

Statement from the Finnish Diabetes Association: Hybrid Pumps as an Effective Solution for Type 1 Diabetes Treatment in Finland According to the Finnish Diabetes Association, hybrid pumps effectively improve the treatment balance and quality of life for people with type 1 diabetes. This leads to savings due to a reduction in diabetes-related complications and acute issues. Additional savings arise from maintaining functional and working capacity. According to an insulin pump survey published by the Finnish Diabetes Association in the spring of 2023, insulin pumps are used less frequently in Finland than in other parts of Europe, and hybrid pumps make up only a fraction of the pumps used. At the same time, there is a significant treatment gap for insulin-dependent diabetes in Finland. Only 26% of Finns aged 18–74 with type 1 diabetes meet the recommended treatment goal for glycated hemoglobin (HbA1c <53 mmol/mol). Less than one-third of children and adolescents under 18 achieve the target. Read the full statement on the Diabetes Association's website: https://loom.ly/LGYuDBw

25

Navigate Medical Device Innovation with Expert Due Diligence MDS Denmark is proud to introduce our specialized Medical Device Due Diligence Service, designed to illuminate the path toward successful funding decisions and market entry. Traditional due diligence processes often fall short when applied to the unique challenges of the medical device sector. Recognizing this, our service goes beyond financial scrutiny to address the multifaceted risks inherent in this industry. With a focus on both the scientific and regulatory landscapes, we provide a comprehensive evaluation to support your strategic decisions for startups and investors alike. Key Features of Our Due Diligence Service: In-depth Intended Use Analysis: We meticulously assess whether the device addresses a genuine medical need, evaluating its potential to significantly improve patient outcomes or enhance quality of life. This crucial step ensures that the device's value proposition is both clear and compelling. Rigorous Clinical Evidence Review: Our experts scrutinize the device's clinical evidence, ensuring compliance with both EU & FDA requirements. From proof of concept to scientific publications, we evaluate the breadth and depth of support for the device's efficacy and safety. Expert Competence Evaluation: The success of a medical device venture often hinges on the competence of its team. We delve into the technical expertise, preclinical development experience, financial acumen, and networking capabilities of the management team, ensuring they are equipped to navigate the journey ahead. Strategic Regulatory Insight: Our service provides invaluable insights into regulatory strategies, highlighting potential challenges and advising on market entry strategies. This perspective is crucial for aligning product development with regulatory expectations. Comprehensive Risk Management Assessment: We identify technical, design, market, and team risks, providing strategies to minimize potential financial and legal consequences. This holistic risk assessment is foundational for building investor confidence and securing funding. Our Medical Device Due Diligence Service is more than an evaluation—it's a strategic tool for driving success. For startups, it's an opportunity to refine your pitch, emphasizing your device's unique value and readiness for market challenges. For investors, it provides a detailed, nuanced understanding of a potential investment's viability and market potential. Interested in exploring how our Medical Device Due Diligence Service can enhance your strategy and decision-making? Contact us at Kristian@mdsdenmark.dk or call +45 2712 4712. You can also book a meeting with us on here: https://lnkd.in/dky_c__A Let's Navigate the Future of Medical Device Innovation Together. #MedicalDevices #DueDiligence #RegulatoryCompliance #QualityManagement #MDR #IVDR

3

1 Kommentar

🏡 𝐁𝐄𝐓𝐀. 𝐇𝐄𝐀𝐋𝐓𝐇 𝐱 𝐑𝐨𝐜𝐡𝐞 𝐩𝐫𝐨𝐣𝐞𝐜𝐭 𝐚𝐢𝐦𝐬 𝐭𝐨 𝐛𝐫𝐢𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐚𝐫𝐞 𝐢𝐧𝐭𝐨 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬’ 𝐡𝐨𝐦𝐞𝐬. ‘Blood Tests at Home’, the healthcare innovation project selected from our ‘Industry Call’ in partnership with Roche Danmark last summer, aims to enhance the quality of life for cancer patients by bringing care into their homes while also freeing up hospital resources for other important tasks. Before beginning chemotherapy, patients undergo blood tests to ensure they have adequate levels of white blood cells, platelets, hemoglobin and immune system function. Today, these blood tests must be done in hospital – and some patients require ongoing testing three to four times a week. Such frequent hospital visits place significant demands on patients and their caregivers. The Blood Tests at Home project aims to improve the quality of life for cancer patients and their caregivers through a new technology that enables them to perform these critical blood tests at home, eliminating the burden of multiple weekly hospital visits. In collaboration with partners in Germany and Poland, the team behind Blood Tests at Home is piloting a home-testing solution with 150 cancer patients from five hospitals located in Denmark, Germany and Poland. With this solution, the patient pricks their finger and completes a few simple steps to prepare the sample before inserting it into a scanner. When the results are ready, the patient photographs and submits them via the system’s dedicated health platform. The final iteration of the solution, which is under development, will be fully automated to send the results directly to the hospital. The team believes that this solution will make life easier for cancer patients undergoing chemotherapy by reducing the number of hospital visits – and the risk of infection inherent in those visits. ‘In practical terms, it can help patients spend more time at home with their loved ones instead of travelling to central laboratories for blood tests. That's how it's done today. This is a new way of thinking, where diagnostic equipment is brought into patients' homes’, explains Niels Henrik Holländer, Chief Physician in the Oncology Department at Sjællands Universitetshospital in Næstved, and a member of the project team behind Blood Tests at Home along with Keld Hundewadt. The team’s ambition is to develop a solution that enhances patient treatment, improves their quality of life and benefits the overall healthcare system in Denmark – but which can also be scaled and extended to all other types of cancer patients with similar needs in Europe and the rest of the world.

32

3 Kommentarer

Together with MSD and Healthanea we're raising awareness for lung cancer using new and novel approaches, bringing together digital and in-person healthcare provision at scale.   Lung cancer presents a significant health challenge in Sweden and globally, with high mortality rates and substantial financial burdens on healthcare systems. The symptoms of lung cancer often appear late in the course of the disease, resulting in a late-stage diagnosis and decreased chances of a positive outcome for patients.   MSD’s “Lung Health” chatbot aims to increase public awareness of the early signs of lung cancer and facilitate easier access to follow-up consultation for its users, although is not used in diagnostic purposes.   We hope that this new “Lung Health” chatbot will emphasize how digitally enabled solutions can facilitate easier contact with healthcare providers and that, subsequently, evidence-based screening protocols by Kry can shorten the time-to-diagnosis and treatment. This is a great example of how we can integrate digital technology into healthcare, providing patients with direct access to medical assistance. Read more:  https://lnkd.in/dcB3-AQh Find out more: https://lnkd.in/eR5kPtxZ Johannes Schildt 🇺🇦 Kalle Conneryd Lundgren Claes Ruth Fredrik Nylander Lukas Didon Edvard Hedenius #digitalhealthcare #healthcare #lungcancer

37

Empowering Swedish Healthcare for a Brighter Tomorrow Sweden’s healthcare system is on the cusp of a transformative era. The Swedish Association of Health Professionals Vårdförbundet has shone a light on the need for change, revealing that 30% of healthcare workers are working part-time due to high work load. This statistic isn’t just a number—it’s a call to action to create a work environment that supports our dedicated professionals. Despite the challenges, there’s a silver lining. The resilience shown by healthcare workers under 35 is nothing short of inspiring. Their commitment to patient care, even when considering their future, underscores the passion that drives our healthcare system. Strikes and collective actions are a testament to the strength and unity of our healthcare community. They highlight the dedication of our workers to advocate for a system that allows them to give their best to patients. In the wake of Covid-19, our healthcare leaders have been navigating uncharted waters, striving to balance budgets while maintaining quality care. Their efforts haven’t gone unnoticed, and their leadership has paved the way for a new chapter in healthcare management. As we move forward, we’re seeing a renewed focus on wellbeing and job satisfaction. Initiatives are underway to reduce overbooking and ensure that every healthcare worker can provide care without the fear of burnout. Together, we’re building a future where healthcare workers are celebrated, supported, and empowered to thrive. A future where every member of our healthcare family can look forward to a fulfilling career, filled with opportunities for growth and innovation. Let’s continue to champion a healthcare system that’s not only sustainable but also a source of national pride—a system where caring for those who care for us is our utmost priority.

44

2 Kommentarer

Launching a startup in the MedTech industry is an exhilarating journey filled with innovation and the promise of transforming healthcare. However, one of the most daunting hurdles we face is navigating the complex regulatory landscape. Crafting a robust regulatory strategy is not just a requirement but a critical success factor that can significantly influence our company's trajectory. But what is it and what does it do for you? Read more here ⬇

10

Welcome to Ascelia Pharma AB Investor Update: Bringing Orviglance to Patients Today Ascelia Pharma AB welcomes investors, analysts and media to the virtual update and live Q&A, where executive management further explains the strong Phase 3 headline results and plans for the upcoming regulatory and commercialization activities. Presentations are available on the Company’s website and the live Q&A starts on Tuesday, 7 May at 14:00 CEST. #investorupdate #orphanoncology #Phase3

8

I had a great conversation with Lars Brock Nilsen at HealthTalk (in Norwegian) about #AI in health care and how we utlize this in DoMore Diagnostics to determine patient risk profile and enable personalized #cancertreatment. While there are some pitfalls implementing AI solutions, the upside is tremendous. Let me know if you have further thoughts or comments!

53

🔍 Johan Carlegrim, President at Sectra Medical Education, recently shared his perspective on the current state and future challenges of diagnostic imaging. From a growing demand spurred by an aging population and chronic diseases to a pronounced workforce crisis, how do we keep this critical element of healthcare from failing? Read the full article here >> https://lnkd.in/gcNuUUb3 #MedEd #SectraInsights #SectraEducationPortal

75

"We must win the battle for talent!" Business column in Nordic Life Science News by MVA chairman, Niels Abel Bonde In the old days, the major pharmaceutical companies and successful life science companies were generally in the driving seat and could pick and choose from qualified candidates. But times have changed and to recruit the new generations we need a more holistic approach. Fortunately, Denmark and Sweden are generally well positioned in the new global battle for talent, but the battle is intensifying, and we cannot rest on our laurels. Hopefully the forthcoming updated national life science strategies of both countries will address this crucial aspect head-on. A coordinated approach highlighting the attractiveness of the two leading clusters and pillars of Nordic life science, the bi-national Danish-Swedish Medicon Valley region and the Stockholm-Uppsala region, would be even better. Is that too much “bridge building” to ask for? Read full column in Nordic Life Science Magazine and feel free to comment! https://lnkd.in/dZDRUfjX David Munis Zepernick Ulf G Andersson Anette Steenberg Malin Otmani Karen Ellemann Micael Gyorei Niels Christian Ganderup Niels Thun Andersen Dan Rosenberg Alexander Leopold Watts Merete Sandager

29

2 Kommentarer

🎧 Discover how Alcon is mastering digital transformation with strategic lighthouse projects in the Nordics, aiming to deliver personalized and integrated customer experiences. 🎧 Get all the insights in our podcast: https://lnkd.in/dBReP34E #Medicaldevice #Pharma #Healthcare #Podcast

11

In collaboration with Proteket, Kulzer Nordic arranged a webinar on clinical cases around prostheses and the problems that can arise and solutions to these. Thank you Kim and Proteket for a good collaboration and successful webinar. We also extend a big thank you to all participants for their good response and turnout. Are you interested in participating in the next webinar? Sign up for Kulzer's newsletter via the QR code for information about products, news, tips & tricks and upcoming webinars. #proteket #kulzer #kulzernordic #prostheses #webinarie

9

1 Kommentar

Recent scientific publication reveals that PExA may facilitate rapid diagnosis of Primary Graft Dysfunction (PGD), a prevalent complication among lung transplant patients. 🫁 🗣️Professor Sandra Lindstedt at Lund University comments: We have built up solid experience with PExA in our lung research and can now begin to see patterns for disease directly through particle flow measurements and indirectly through the protein profiling we do on the collected material. This creates new conditions for an increased understanding and early detection of lung diseases, which can be of great importance for the efficiency of healthcare, but of course also for all patients with lung diseases.  Read the full press release below / Läs hela pressmeddelandet nedan: 👇🏼 English (Google translated) https://lnkd.in/d28K6pDt Svenska : https://lnkd.in/dWJucvup

17

A Journey Through Leadership and Healthcare Patricia Enocson recently left her role as HR Director for Karolinska Sjukhuset and is now looking forward to a career as an Executive Interim Manager in the USA. We have talked to her about leadership and the challenges within the healthcare sector. What challenges does the healthcare sector face, especially after the pandemic? "The challenges are significant, particularly in ensuring the right skills and finding experienced healthcare professionals. The workload is still high after the pandemic, and we need to think about new professional categories, analyse how future healthcare will look like, and how it will be administered, both at home and in our hospitals. Managers and HR functions, in general, must adapt for the future; we can’t stand still but anticipate the upcoming needs from a broader perspective. One important thing the pandemic brought with it is the realization that rapid adaptation is possible. At Karolinska Sjukhuset, HR became an active and equal partner; it's important that HR is not a separate guild but integrated into the business. CEO, CFO, and HR form an important trio to support managers so that together we can drive the business forward." What attracts you to start a career as an Executive Interim Manager? "After five years at Karolinska Sjukhuset, I want to try the role as an Interim Manager. Operationally driving change, development, and improvement for specific needs and projects appeal to me. I want to explore new industries in personnel-intensive, international, and profit-driven organizations. Executive Interim Management gives me a fantastic opportunity to share my experiences and to support management and staff. As an interim, you have to give your all; there are no 40-hour weeks. I have myself engaged Interim Managers and know that they are 'up and running' within two weeks, which provides an enormous boost when facing challenges and lacking the right expertise." Read our interview with Patricia here: https://lnkd.in/dZ-CaKg2 #interimmanagement #hr #healthcare 

19

If we focus only on the emissions from the inhaler we risk losing track of the emission intensive parts of the patient care pathway According to NICE the CO2e emission difference between a powder and an MDI inhaler is more than factor 20. This is all great and we should also celebrate the progress and the insights leading us to save a lot of CO2e from converting to powder inhalers where possible and safe. However; according to the SENTINEL project summary, SABA* accounted for more than 50% of total inhaler use and inhaler-related emissions in most countries analysed. The total SABA-related emissions were estimated at 2.7 million tonnes carbon dioxide equivalents, accounting for 70% of total inhaler-related emissions. So it's great that we're transitioning to powder inhalers - but the main emissions are to be caught in adherence and preventing emergency situations for patients with respiratory NCDs**. *Short-acting beta-agonists (SABAs) are a class of bronchodilators used to treat asthma symptoms quickly. They are primarily inhaled via a rescue inhaler or a nebulizer. **A non-communicable disease (NCD) is a disease that is not transmissible directly from one person to another. Image credit - me having a fun dance with Dall-e image generation.

19

6 Kommentarer

Welcome to 🇩🇰 Denmark's Pioneering Life Science Investor Network 🚀 🧬 💰 Denmark's life science industry is a beacon of innovation💡, with companies like Novo Nordisk, Lundbeck, Coloplast, and Ambu leading the charge. This thriving sector has given rise to a robust start-up and scale-up scene, mirroring the success of its established players. Yet, for investors, navigating the sea of opportunities, especially in early-stage ventures, is no easy feat. These young companies often feature strong science and novel engineering with the potential for significant impact, but they also come with high risks. Historically, Denmark lagged in early-stage investing, but this trend is shifting, spearheaded by the dynamic life science industry. The question remains: How can we connect risk-willing capital with promising ventures when many investors lack medical or engineering backgrounds? Today marks the launch of an exclusive life-science investor network, uniting angels, accelerators and VCs across Denmark. This network aims to foster mutual support, though its precise framework is still under development. Over the next six months, similar events will be hosted nationwide to fine-tune the network's value proposition and structure. Today's discussions highlighted many interesting themes and challenges, underscoring a genuine desire to collaborate on derisking early life science investments. A big thank you to Novo Nordisk Foundation, DTU Entrepreneurship, DTU Science Park and Jesper Højberg Christensen for taking initiative spearheading this initiative and to ALK for hosting the inaugural event 🙏 In the picture, CEO Steen Donner from DTU Science Park welcomes the 60 participants in today's kick-off📣

135

9 Kommentarer

💦 Coloplast expands its Luja portfolio with next generation catheter for women Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients, and seven out of ten users feel confident that it empties their bladder completely without needing to reposition the catheter,” says Nicolai Buhl Andersen, Executive Vice President of Innovation. Urinary tract infections remain a major concern and challenge for men and women using catheters. Flow stops and blockage of conventional catheter eyelets during catheterisation increase the risk of leaving residual urine behind in the bladder, which raises the risk of bacteria growth and is a well-known UTI risk factor2. “I am excited that the Micro-hole Zone Technology will now be available for female catheter users. The new female catheter has 50+ micro-holes, enabling complete bladder emptying in one free flow, and I believe this technology will set a completely new standard in the market,” says Nicolai Buhl Andersen. Luja with Micro-hole Zone Technology for female users will launch across all Coloplast’s key markets over the next 12 months, starting in Denmark and Italy in May 2024. Read more online: https://lnkd.in/eg45GKjD 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

4

Sweden: Pharma M&A - Impilo have sold a stake in Immedica Pharma AB to KKR for an undisclosed amount and is reinvesting as an equal shareholder. Founded in 2018, Immedica has a portfolio and pipeline of drugs primarily within haematology and oncology as well as genetic and metabolic diseases for rare conditions with high unmet medical need. 2023 pro forma sales were $94m with annual growth of more than 50%, and adjusted EBITDA of $35m. KKR is investing through its KKR Health Care Strategic Growth Fund II, a US$4bn fund focused on investing in high-growth health care companies. Morgan Stanley were financial and Latham & Watkins and Mannheimer Swartling legal advisors to Impilo and Bank of America were financial and Gibson Dunn , Setterwalls Advokatbyrå and Cooley LLP legal advisors to KKR. Jamieson Corporate Finance advised the management team. READ Immedica's Annual Business Review here https://lnkd.in/eiucDHUa #healthcare #pharma #lifesciences #privateequity anders edvell Magnus Edlund Wim De Vlieger Kugan Sathiyanandarajah Linda Holmström Robbie McLaren Eveline Van Keymeulen Ian Jamieson

34

🌟 Meet Therese: Pioneering Healthcare Innovation at Gustafkliniken and reducing admin with 80% 🌟 Therese Varre Almesjö, a visionary physician and the driving force behind Gustafkliniken Vårdcentral is on a mission to transform healthcare. But Gustafkliniken isn’t your typical medical center – it’s a place where healing goes beyond treating physical ailments; it’s about nurturing the soul. What sets Gustafkliniken apart? * Patient-Tailored Hours: They believe healthcare should adapt to patients, not the other way around. That’s why we offer personalized opening hours, even on weekends. * Soothing Spaces: Their stunning interior design creates a serene environment, essential for holistic well-being. * Exceptional Staff: The highly competent team prioritizes patient care, ensuring every visit is exceptional. 🌐 Innovating at the Intersection of Tech and Medicine Collaborating with Therese and her team has been a journey of discovery. Our latest breakthrough? A configurable functionality that empowers healthcare workers to send patients deep links for self-scheduling. This innovation slashes administrative overhead by up to 80%, freeing up valuable time for what matters most – patient care. 🚀 A Future Beyond Treatment Together, we’re shaping a future where healthcare centers aren’t just clinical spaces; they’re sanctuaries for recovery and innovation. Join us on this transformative journey! 💙 #healthcareinnovation #Gustafkliniken #wellness #techandhealthcare

11